Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690587 | 1.00 | EPHX1 (0.47) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL7694142 | 1.00 | EPHX1 (0.47) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL4679499 | 0.98 | EPHX1 (0.44) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL4674368 | 0.93 | — | — | |
| SCHEMBL4673392 | 0.88 | — | — | |
| SCHEMBL19244484 | 0.83 | EPHX1 (0.44) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL20856638 | 0.83 | EPHX1 (0.44) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL872686 | 0.83 | EPHX1 (0.44) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL872685 | 0.83 | EPHX1 (0.44) | EPHX1NAAAHTTCA12CA1 | |
| Ethane SCHEMBL28092403 | 0.82 | EPHX1 (0.47) | EPHX1NAAAHTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107073002-B | The nucleoside derivates that the 4 '-vinyl as respiratory syncytial virus (RSV) rna replicon inhibitor replace | 里博科学有限责任公司 | 2019-10-15 | — | — | CN | claimed |
| EP-2944633-B1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-01-31 | — | — | EP | claimed |
| CN-107073002-A | The nucleoside derivates replaced as 4 ' vinyl of respiratory syncytial virus (RSV) rna replicon inhibitor | 里博科学有限责任公司 | 2017-08-18 | — | — | CN | claimed |
| US-20150284358-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-10-08 | — | — | US | claimed |
| US-7087597-B1 | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-08 | — | — | US | claimed |
| EP-1213290-B1 | DIHYDROBENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2005-04-20 | — | — | EP | claimed |
| WO-1992014706-A1 | CYCLOPENTANE-DERIVED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1992-09-03 | — | — | WO | claimed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-113038948-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| EP-0470256-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1991013089-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-05 | — | — | WO | disclosed |
| EP-0008540-B1 | 2-ARYL-1,3-INDANDIONE DERIVATIVES AND COMPOSITIONS COMPRISING THEM FOR CONTROLLING ECTOPARASITIC ACARINA | UNION CARBIDE CORPORATION (US) | 1984-10-24 | — | — | EP | disclosed |
| US-4386086-A | ENOL DERIVATIVES OF 2-ARYL-1,3-INDANDIONES | UNION CARBIDE CORPORATION (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0008540-A2 | 2-aryl-1,3-indandione derivatives and compositions comprising them for controlling ectoparasitic acarina | UNION CARBIDE CORPORATION (US) | 1980-03-05 | — | — | EP | disclosed |
| US-4104043-A | Esters of 3-hydroxyindone compounds as herbicides and miticides | UNION CARBIDE CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
| US-4091006-A | MITICIDES AND HERBICIDES | UNION CARBIDE CORPORATION (US) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284358-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | EPHX1 897/4885NAAA 2030/4885HTT 747/4885 |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPY2R | EPHX1 1663/4885NAAA 969/4885HTT 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.